Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jos Nauta"'
Autor:
Laura Colombo, Sanjay Hadigal, Jos Nauta, Alona Kondratenko, Jutta Rogoll, Serge van de Witte
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 88-101 (2024)
ABSTRACTIntroduction This paper summarizes the safety and immunogenicity data of Influvac Tetra across all age groups starting from 6 months of age, obtained during its clinical development program.Areas covered The article covers the clinical develo
Externí odkaz:
https://doaj.org/article/ba853abf24674c35995fc59eb2b552c1
Autor:
Melanie, Moeller-Arendt, Serge, van de Witte, Jos, Nauta, Hanka, de Voogd, Jutta, Rogoll, Thomas, Nisslein
Publikováno v:
Vaccine. 41:606-613
In 2014, the European Medicines Agency (EMA) set out requirements for an enhanced safety surveillance for seasonal influenza vaccines. This paper presents data from the yearly Enhanced Passive Safety Surveillance (EPSS) implemented for Influvac® sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1e7db79ada404c3c9a33b9bc4be29f
https://doi.org/10.1016/j.vaccine.2022.12.001
https://doi.org/10.1016/j.vaccine.2022.12.001
Publikováno v:
Vaccine. 40:2626-2634
Children are an important target group for influenza vaccination, but few studies have prospectively evaluated influenza vaccine efficacy (VE) in children under 3 years of age. This was a randomized Phase III trial to assess the efficacy, immunogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e48c130bb5b85be2c69c074f719a7307
https://doi.org/10.1016/j.vaccine.2022.02.088
https://doi.org/10.1016/j.vaccine.2022.02.088
Autor:
null Anke L. Stuurman, null Miriam Levi, null Philippe Beutels, null Hélène Bricout, null Alexandre Descamps, null Gaël Dos Santos, null Ian McGovern, null Ainara Mira‐Iglesias, null Jos Nauta, null Laurence Torcel‐Pagnon, null Jorne Biccler, null DRIVE consortium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f13f5e4897d2e249d1f6799a6c8642f2
https://doi.org/10.1111/irv.13087/v2/response1
https://doi.org/10.1111/irv.13087/v2/response1
Autor:
Daryl J. Hoban, Jos Nauta
Publikováno v:
The Open Infectious Diseases Journal. 13:1-9
Objective: A meta-analysis was performed to explore the relative effects of clarithromycin and amoxicillin (with or without clavulanate potassium) in the treatment of acute maxillary sinusitis. Methods: Six studies were identified in the peer-reviewe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::811b34ea8f72e316ab1407aedda4d812
https://doi.org/10.2174/1874279302113010001
https://doi.org/10.2174/1874279302113010001
Autor:
Javier Díez-Domingo, Laurence Torcel-Pagnon, Antonio Carmona, Odile Launay, Gaël Dos Santos, Caterina Rizzo, Mendel Haag, Anke Stuurman, Jos Nauta, Alfredo Vannacci, Simon de Lusignan, Elena Del Rey, Miriam Levi, Bruno Lina, Stefania Bellino, Samantha Nye, Pieter Neels, Hanna Nohynek, Cédric Mahé
Publikováno v:
Expert Review of Vaccines
Expert Review of Vaccines, 2022, 21 (12), pp.1701-1710. ⟨10.1080/14760584.2022.2137144⟩
Expert Review of Vaccines, 2022, 21 (12), pp.1701-1710. ⟨10.1080/14760584.2022.2137144⟩
International audience; Introduction: Fighting pandemics requires an established infrastructure for pandemic preparedness, with existing, sustainable platforms ready to be activated. This includes platforms for disease surveillance, virus circulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b6088f0081ce6e036992743c48fbceb
Autor:
Daryl J. Hoban, Jos Nauta
Publikováno v:
Drug Design, Development and Therapy. 13:3551-3558
Introduction Among the bacterial upper respiratory tract infections (UTRIs), the most medically significant is pharyngitis due to Group A beta-hemolytic Streptococci (GABHS). A 2012 meta-review and a 2016 Cochrane systematic review reported favorably
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d62776f01c8118a803c57419c567a3cd
https://doi.org/10.2147/dddt.s205820
https://doi.org/10.2147/dddt.s205820
Autor:
Daryl J. Hoban, Jos Nauta
Publikováno v:
The Open Infectious Diseases Journal. 13:10-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::543d292340b593f4fc61ecd692fbbae7
https://doi.org/10.2174/1874279302113010010
https://doi.org/10.2174/1874279302113010010
Publikováno v:
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 92
To analyse the immunogenicity and safety of inactivated subunit quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) in children and adolescents 3-17 years of age.In this phase III, multicentre, double-blind study, 1200 subje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6beedc042f2977b3d87e655b5de791d
https://pubmed.ncbi.nlm.nih.gov/31838217
https://pubmed.ncbi.nlm.nih.gov/31838217
BACKGROUND Trivalent influenza vaccines (TIVs) offer substantial protection against matching B-strains, however, protection against alternate-lineage B-strains may be enhanced by adding a second B-strain in quadrivalent influenza vaccines (QIVs). In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2ec8c36e39c496c4625d62cb1c43e94
http://hdl.handle.net/11365/1059304
http://hdl.handle.net/11365/1059304